Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors

被引：0
|
作者：
Eiki Ichihara
Daijiro Harada
Koji Inoue
Takuo Shibayama
Shinobu Hosokawa
Daizo Kishino
Shingo Harita
Nobuaki Ochi
Naohiro Oda
Naofumi Hara
Katsuyuki Hotta
Yoshinobu Maeda
Katsuyuki Kiura
机构：
[1] Okayama University Hospital,Department of Allergy and Respiratory Medicine
[2] National Hospital Organization Shikoku Cancer Center,Department of Thoracic Oncology
[3] Ehime Prefectural Central Hospital,Department of Respiratory Medicine
[4] National Hospital Organization Okayama Medical Center,Department of Respiratory Medicine
[5] Japanese Red Cross Okayama Hospital,Department of Respiratory Medicine
[6] Himeji Red Cross Hospital,Department of Respiratory Medicine
[7] Okayama Saiseikai General Hospital,Department of Internal Medicine
[8] Kawasaki Medical School,Department of General Internal Medicine 4
[9] Fukuyama City Hospital,Department of Internal Medicine
[10] Okayama University Graduate School of Medicine,Department of Hematology, Oncology and Respiratory Medicine
[11] Dentistry,Center for Innovative Clinical Medicine
[12] and Pharmaceutical Sciences,undefined
[13] Okayama University Hospital,undefined
来源：
Cancer Immunology, Immunotherapy | 2021年 / 70卷
关键词：
Non-small-cell lung cancer; Immune checkpoint inhibitor; EGFR;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：101 / 106
页数：5
相关论文
共 50 条
  • [1] Characteristics of patients withEGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors
    Ichihara, Eiki
    Harada, Daijiro
    Inoue, Koji
    Shibayama, Takuo
    Hosokawa, Shinobu
    Kishino, Daizo
    Harita, Shingo
    Ochi, Nobuaki
    Oda, Naohiro
    Hara, Naofumi
    Hotta, Katsuyuki
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (01) : 101 - 106
  • [2] Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench
    Jin, Rui
    Zhao, Jing
    Xia, Lexin
    Li, Qin
    Li, Wen
    Peng, Ling
    Xia, Yang
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [3] Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review
    Attili, Ilaria
    Passaro, Antonio
    Corvaja, Carla
    Aliaga, Pamela Trillo
    Del Signore, Ester
    Spitaleri, Gianluca
    de Marinis, Filippo
    [J]. CANCER TREATMENT REVIEWS, 2023, 119
  • [4] YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer
    Li, Ling-Chen
    Chen, Xie-Wan
    Fang, Ling
    Jian, Chun-Li
    Yu, Yong-Xin
    Liao, Xing-Yun
    Sun, Jian-Guo
    [J]. CANADIAN RESPIRATORY JOURNAL, 2023, 2023
  • [5] Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
    Gomes, Jessica Ribeiro
    Cruz, Marcelo Rocha S.
    [J]. ONCOTARGETS AND THERAPY, 2015, 8 : 1137 - 1142
  • [6] Brain metastases in patients with EGFR-mutant non-small-cell lung cancer
    Rosell, Rafael
    Karachaliou, Niki
    [J]. LANCET RESPIRATORY MEDICINE, 2017, 5 (09): : 669 - 671
  • [7] Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer
    Soo, Ross A.
    Kim, Hye Ryun
    Asuncion, Bernadette Reyna
    Fazreen, Zul
    Omar, Mohamed Feroz Mohd
    Herrera, Maria Cynthia
    Lim, Joey Sze Yun
    Sia, Grace
    Soong, Richie
    Cho, Byoung-Chul
    [J]. LUNG CANCER, 2017, 105 : 17 - 22
  • [8] Treatment choice in EGFR-mutant non-small-cell lung cancer
    Brueckl, Wolfgang M.
    [J]. LANCET ONCOLOGY, 2017, 18 (11): : 1425 - 1426
  • [9] Spontaneously expectorated EGFR-mutant non-small-cell lung cancer
    Sumi, Toshiyuki
    Terai, Kotomi
    Chiba, Hirofumi
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (11) : 1094 - 1095
  • [10] Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer
    Cabanero, M.
    Tsao, M. S.
    [J]. CURRENT ONCOLOGY, 2018, 25 : S38 - S44
12345